Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009

American Journal of Epidemiology

Volumn 175, Issue 8, 2012, Pages 827-837

  Lu, Peng Jun ^a   Nuorti, J Pekka ^a,b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Adult; Asthma; Pneumococcal vaccines; Smoking; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGE CLASS; ASTHMA; DATA SET; EPIDEMIOLOGY; HEALTH INSURANCE; HEALTH SURVEY; HEALTH WORKER; IMMUNIZATION; PNEUMONIA; POLYSACCHARIDE; PUBLIC HEALTH; SMOKING; VACCINATION; VACCINE;

ADULT; ARTICLE; ASTHMA; CIGARETTE SMOKING; FEMALE; HEALTH INSURANCE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEOPLASM; PHYSICIAN; UNEMPLOYMENT; UNITED STATES;

ADOLESCENT; ADULT; ASTHMA; FEMALE; HEALTH SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SMOKING; UNITED STATES; VACCINATION; YOUNG ADULT;

UNITED STATES;

EID: 84859728498     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr376     Document Type: Article

References (37)

1. Prevention of pneumococcal disease. recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-24.
2. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Active bacterial core surveillance/emerging infections program network. J Infect Dis. 2010;201(1):32-41.
3. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2009. Atlanta, GA: Centers for Disease Control and Prevention; 2010. (http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.html). (Accessed January 25, 2011).
4. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2010;59(34):1102-1106.
5. US Department of Health and Human Services. Healthy People 2010 (Conference ed., in 2 vols). Washington, DC: US Department of Health and Human Services; 2000.
6. HealthyPeople.gov. Healthy People 2020. Washington, DC: US Department of Health and Human Services; 2010. (http://www.healthypeople.gov/2020/ topicsobjectives2020/pdfs/HP2020objectives.pdf). (Accessed January 24, 2011).
7. Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18-64 years with diabetes or asthma - United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(43):1007-1012.
8. Singleton JA, Greby SM, Wooten KG, et al. Influenza, pneumococcal, and tetanus toxioid vaccination of adults - United States, 1993-7. MMWR CDC Surveill Summ. 2000;49(9):39-62.
9. Centers for Disease Control and Prevention. Vaccination Coverage Estimates From the National Health Interview Survey: United States, 2000. (http://www.cdc.gov/nchs/data/hestat/vaccine-coverage/vaccine-coverage.htm). Atlanta, GA: Centers for Disease Control and Prevention; 2009. (Accessed January 24, 2011).
10. Greby SM, Lu P-J, Euler G, et al. 2009 Adult Vaccination Coverage, NHIS. Atlanta, GA: Centers for Disease Control and Prevention; 2010. (http://www.cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm). (Accessed January 25, 2011).
11. Centers for Disease Control and Prevention. 2009 National Health Interview Survey (NHIS): Public Use Data Release. Hyattsville, MD: National Center for Health Statistics, 2010. (ftp://ftp.cdc.gov/pub/Health-Statistics/ NCHS/Dataset-Documentation/NHIS/2009/srvydesc.pdf). (Accessed December 11, 2010).
12. Recommended adult immunization schedule: United States, 2009. Ann Intern Med. 2009;150:40-44.
13. Shah B, Barnwell B, Bieier G. SUDAAN User's Manual. Version 10.0. Research Triangle Park, NC: Research Triangle Institute; 2008.
14. Korn EL, Graubard BI. Predictive margins (direct standardization). Analysis of Health Surveys. New York, NY: John Wiley & Sons, Inc.; 1999:126-140.
15. Nadel MR, Shapiro JA, Klabunde CN, et al. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med. 2005;142(2):86-94.
16. HealthyPeople.gov. Immunization and Infectious Diseases. Washington, DC: US Department of Health and Human Services; 2010. (http://www.healthypeople.gov/ 2020/topicsobjectives2020/objectiveslist.aspx?topicid=23). (Accessed June 16, 2011).
17. Metersky ML, Dransfield MT, Jackson LA. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest. 2010;138(3):486-490.
18. US Food and Drug Administration. Prevnar 13. Silver Spring, MD: US Food and Drug Administration; 2010. (http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm201667.htm). (Accessed February 24, 2012).
19. Nichol KL, Mac Donald R, Hauge M. Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults. J Gen Intern Med. 1996;11(11):673-677. (Pubitemid 26425484)
20. Nichol KL, Zimmerman R. Generalist and subspecialist physicians' knowledge, attitudes, and practices regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients: a nationwide survey. Arch Intern Med. 2001;161(22):2702-2708. (Pubitemid 33134846)
21. Rehm SJ, Farley MM, File TM Jr, et al. Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults. Postgrad Med. 2009;121(6):101-105.
22. Poland GA, Shefer AM, McCauley M, et al. Standards for adult immunization practices. National Vaccine Advisory Committee, Ad Hoc Working Group for the Development of Standards for Adult Immunization Practices. Am J Prev Med. 2003;25(2):144-150.
23. Missed opportunities for pneumococcal and influenza vaccination of Medicare pneumonia inpatients - 12 Western States, 1995. MMWR Morb Mortal Wkly Rep. 1997;46(39):919-923.
24. Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51(RR-2):1-35.
25. Racial/ethnic disparities in influenza and pneumococcal vaccination levels among persons aged > or =65 years - United States, 1989-2001. MMWR Morb Mortal Wkly Rep. 2003; 52(40):958-962.
26. Singleton JA, Santibanez TA, Wortley PM. Influenza and pneumococcal vaccination of adults aged > or = 65: racial/ethnic differences. Am J Prev Med. 2005;29(5):412-420. (Pubitemid 41817392)
27. Egede LE, Zheng D. Racial/ethnic differences in adult vaccination among individuals with diabetes. Am J Public Health. 2003;93(2):324-329. (Pubitemid 36159404)
28. Egede LE, Zheng D. Racial/ethnic differences in influenza vaccination coverage in high-risk adults. Am J Public Health. 2003;93(12):2074-2078. (Pubitemid 38480125)
29. Centers for Disease Control and Prevention. Interim Guidance for Use of 23-Valent Pneumococcal Polysaccharide Vaccine During Novel Influenza A (H1N1) Outbreak. Atlanta, GA: Centers for Disease Control and Prevention; 2010. (http://www.cdc.gov/h1n1flu/guidance/ppsv-h1n1.htm). (Accessed December 11, 2010).
30. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008;47(10):1328-1338.
31. Mac Donald R, Baken L, Nelson A, et al. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med. 1999;16(3):173-177. (Pubitemid 29152564)
32. Shenson D, Dimartino D, Bolen J, et al. Validation of self-reported pneumococcal vaccination in behavioral risk factor surveillance surveys: experience from the Sickness Prevention Achieved Through Regional Collaboration (SPARC) program. Vaccine. 2005;23(8):1015-1020. (Pubitemid 40037650)
33. Bayas JM, Izquierdo C, Ruiz L, et al. Validity of self-reported pneumococcal vaccination status in the elderly in Spain. Vaccine. 2009;27(34):4560-4564.
34. Skull SA, Andrews RM, Byrnes GB, et al. Validity of self-reported influenza and pneumococcal vaccination status among a cohort of hospitalized elderly inpatients. Vaccine. 2007;25(25):4775-4783. (Pubitemid 46818615)
35. Zimmerman RK, Raymund M, Janosky JE, et al. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine. 2003;21(13-14):1486-1491. (Pubitemid 36263190)
36. Mangtani P, Shah A, Roberts JA. Validation of influenza and pneumococcal vaccine status in adults based on self-report. Epidemiol Infect. 2007;135(1):139-143. (Pubitemid 44811498)
37. Smith KJ, Wateska AR, Nowalk MP, et al. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307(8):804-812.